FDA July 2026 Peptide Meeting: What Patients Need to Know About Access, Approval, and Safety Meto blog FDA has removed certain bulk drug substances that were placed on the category two list and has announced it will consult the Pharmacy Compounding Advisory Committee (PCAC) for potential future inclusion of FDA Peptide Category 2 Removal & Public Meeting July 23rd Mansi Hukmani posted on the topic LinkedIn FDA Warning: Hidden Dangers of Smuggled Tirzepatide boomrx #peptides #fda #compoundingpharmacy #clinicalmedicine #patientaccess BoomRX